- Home
- RBOT vs RNXT Comparison
RBOT vs RNXT Comparison
Compare RBOT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- RNXT
- Stock Information
- Founded
- RBOT 2014
- RNXT 2012
- Country
- RBOT United States
- RNXT United States
- Employees
- RBOT N/A
- RNXT N/A
- Industry
- RBOT Medical Specialities
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- RNXT Health Care
- Exchange
- RBOT Nasdaq
- RNXT Nasdaq
- Market Cap
- RBOT 38.3M
- RNXT 44.0M
- IPO Year
- RBOT N/A
- RNXT 2021
- Fundamental
- Price
- RBOT $5.75
- RNXT $1.13
- Analyst Decision
- RBOT Hold
- RNXT Strong Buy
- Analyst Count
- RBOT 1
- RNXT 2
- Target Price
- RBOT $7.00
- RNXT $7.50
- AVG Volume (30 Days)
- RBOT 132.2K
- RNXT 579.1K
- Earning Date
- RBOT 11-10-2025
- RNXT 11-13-2025
- Dividend Yield
- RBOT N/A
- RNXT N/A
- EPS Growth
- RBOT N/A
- RNXT N/A
- EPS
- RBOT N/A
- RNXT N/A
- Revenue
- RBOT N/A
- RNXT $662,000.00
- Revenue This Year
- RBOT N/A
- RNXT $2,895.35
- Revenue Next Year
- RBOT N/A
- RNXT $313.04
- P/E Ratio
- RBOT N/A
- RNXT N/A
- Revenue Growth
- RBOT N/A
- RNXT N/A
- 52 Week Low
- RBOT $5.00
- RNXT $0.75
- 52 Week High
- RBOT $19.00
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- RBOT 45.38
- RNXT 46.07
- Support Level
- RBOT $5.60
- RNXT $1.12
- Resistance Level
- RBOT $6.19
- RNXT $1.15
- Average True Range (ATR)
- RBOT 0.55
- RNXT 0.08
- MACD
- RBOT -0.01
- RNXT -0.01
- Stochastic Oscillator
- RBOT 14.01
- RNXT 32.00
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.